Table 1 Circulating miRNAs associated with clinical outcome in stage II-III BC patients*
Metastatic Relapse in All patients in the Study Cohort | ||||
|---|---|---|---|---|
| Â | Relapsed | Non-relapsed | Log fold diff. (relapsed vs. non-relapsed) | Â |
Game name | ( N = 11) | ( N = 31) | Â | P value |
| Â | Ave. counts (normalized) | Ave. counts (normalized) | Â | Â |
hsa-miR-375 | 2, 177 | 14, 316 | -1.90 | 5.89E-05 |
hsa-miR-122 | 532, 501 | 168, 532 | 1.35 | 2.98E-03 |
NCT Response in HER2 + Patients | Â | Â | Â | Â |
| Â | pCR | Non-pCR | Log2 fold diff (pCR vs. non-pCR) | Â |
Game name | (N = 12) | ( N = 11) | Â | P value |
Ave. counts (normalized) | Ave. counts (normalized) | Â | Â | Â |
hsa-miR-375 | 32, 629 | 4, 014 | 3.02 | 1.10E-09 |
hsa-miR-184 | 245 | 31 | 2.99 | 2.59E-09 |
hsa-miR-1299 | 454 | 89 | 2.35 | 1.24E-06 |
hsa-miR-196a | 989 | 239 | 2.05 | 1.79E-05 |
hsa-miR-381 | 384 | 1, 235 | -1.69 | 2.48E-04 |
hsa-miR-410 | 129 | 364 | -1.50 | 1.09E-03 |
hsa-miR-1246 | 19, 969 | 55, 915 | -1.49 | 1.16E-03 |